Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome

Elsamany, Shereef Ahmed; Al-Fayea, Turki M; Alzahrani, Abdullah Said; Abozeed, Waleed Nabeel; Darwish, Waseem; Farooq, Mian Usman; Almadani, Ahmed Salahuddin; Bukhari, Esraa Ahmed

추천

검색

자료유형: 학술저널

저자정보: Elsamany, Shereef Ahmed (Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City) Al-Fayea, Turki M (King Abdulaziz Medical City) Alzahrani, Abdullah Said (Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City) Abozeed, Waleed Nabeel (Department of Clinical Oncology, Mansoura University Hospital) Darwish, Waseem (King Abdulaziz Medical City) Farooq, Mian Usman (Department of Research, King Abdullah Medical City) Almadani, Ahmed Salahuddin (Department of Research, Um Alqora University) Bukhari, Esraa Ahmed (Department of Research, Um Alqora University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제7호

발행연도: 2015.1

수록면: 2,987 - 2,991 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The prognostic role of thyroid transcription factor-1 (TTF-1) expression in lung cancer has been assessed but with inconsistent results. The present study aimed to evaluate the prognostic value of TTF1 expression in advanced non-squamous non-small cell lung cancer (NSCLC). Materials and Methods: In this retrospective study, patients with stage IIIB-IV non-squamous NSCLC were enrolled. Progression free survival (PFS) and overall survival (OS) were assessed according to TTF1 expression status, age categories (${\leq}60$ vs >60 years), gender, performance status (PS) (0-2 vs 3-4), type of 1st line chemotherapy (pemetrexed containing vs others) and EGFR status. Results: A total of 120 patients were included. In univariate analysis, PFS was improved in patients with PS 0-2 (7.0 vs 2.0 months, p=0.002) and those who received pemetrexed-containing chemotherapy (9.2 vs 5.8 months, p=0.004). OS was improved in female patients (23.0 vs 8.7 months, p<0.0001), PS 0-2 (14.4 vs 2.0 months, p<0.0001), those with pemetrexed-containing chemotherapy (17.0 vs 11.0 months, p=0.019), TTF1-positive (12.8 vs 5.8 months, p=0.011) and EGFR- mutant patients (23.0 vs 11.7 months, p=0.006). In multivariate analysis, male gender (HR=2.34, p=0.025) and non-pemetrexed containing therapy (HR=2.24, p=0.022) were independent predictors of worse PFS. Wild EGFR status (HR=2.49, p=0.015) and male gender (HR=2.78, p=0.008) were predictors of worse OS. Conclusions: Pemetrexed-containing therapy significantly improved PFS while OS was improved in EGFR mutant patients. Female patients had better PFS and OS. TTF1 expression was not a prognostic marker in advanced non-squamous NSCLC.

#TTF1 #prognosis #advanced #lung cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!